DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-5.4%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.04B
AUM Growth
+$5.04B
(-4%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
3.28%
Top 10 Holdings %
Top 10 Hldgs %
52.76%
Holding
153
New
45
Increased
20
Reduced
17
Closed
29
Top Buys
| 1 |
United Therapeutics
UTHR
|
$84.8M |
| 2 |
Pfizer
PFE
|
$84.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$69.3M |
| 4 |
Insmed
INSM
|
$34.9M |
| 5 |
Vera Therapeutics
VERA
|
$25.2M |
Top Sells
| 1 |
WAY
Waystar Holding Corp
WAY
|
$121M |
| 2 |
Owens & Minor
OMI
|
$64.2M |
| 3 |
Alignment Healthcare
ALHC
|
$51M |
| 4 |
Galapagos
GLPG
|
$38.8M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$31.3M |
Sector Composition
| 1 | Healthcare | 87.58% |
| 2 | Real Estate | 0.01% |
| 3 | Technology | 0.01% |
| 4 | Consumer Discretionary | 0.01% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MTSR
51
Metsera, Inc. Common Stock
MTSR
$3.75B
| $13.6M | 0.27% |
+500,000
| New | +$13.6M |
|
52
DocGo
DCGO
$152M
| $13.3M | 0.26% |
5,051,500
-2,144,456
| -30% | -$5.66M |
|
53
10x Genomics
TXG
$1.66B
| $13.1M | 0.26% |
1,503,594
+6,594
| +0.4% | +$57.6K |
|
54
Pulmonx
LUNG
$67.6M
| $12.7M | 0.25% |
1,890,000
+355,237
| +23% | +$2.39M |
|
|
BBNX
55
Beta Bionics, Inc. Common Stock
BBNX
$855M
| $12.4M | 0.25% |
+1,016,000
| New | +$12.4M |
|
|
ZBIO
56
Zenas BioPharma, Inc. Common Stock
ZBIO
$722M
| $12.3M | 0.24% |
1,562,942
| – | – |
|
57
Foghorn Therapeutics
FHTX
$298M
| $11.9M | 0.23% |
3,255,514
| – | – |
|
58
NovoCure
NVCR
$1.35B
| $11.6M | 0.23% |
+650,119
| New | +$11.6M |
|
59
Opko Health
OPK
$1.1B
| $11.5M | 0.23% |
+6,906,362
| New | +$11.5M |
|
60
Delcath Systems
DCTH
$381M
| $10.4M | 0.2% |
+813,106
| New | +$10.4M |
|
61
GH Research
GHRS
$870M
| $10.2M | 0.2% |
+925,000
| New | +$10.2M |
|
62
RxSight
RXST
$364M
| $9.91M | 0.2% |
+392,332
| New | +$9.91M |
|
63
Simulations Plus
SLP
$289M
| $8.68M | 0.17% |
+354,089
| New | +$8.68M |
|
64
Dyne Therapeutics
DYN
$1.92B
| $8.5M | 0.17% |
812,408
+376,755
| +86% | +$3.94M |
|
65
Vaxcyte
PCVX
$4.17B
| $8.5M | 0.17% |
225,000
| – | – |
|
|
SION
66
Sionna Therapeutics, Inc. Common Stock
SION
$1.08B
| $7.81M | 0.15% |
+747,000
| New | +$7.81M |
|
67
Spyre Therapeutics
SYRE
$1.02B
| $7.26M | 0.14% |
450,000
| – | – |
|
68
Structure Therapeutics
GPCR
$1.14B
| $6.46M | 0.13% |
373,407
| – | – |
|
69
Neuropace
NPCE
$310M
| $6.15M | 0.12% |
+500,000
| New | +$6.15M |
|
70
Perspective Therapeutics
CATX
$251M
| $6.03M | 0.12% |
2,829,413
-109,341
| -4% | -$233K |
|
71
Neurogene
NGNE
$284M
| $5.23M | 0.1% |
446,880
-1,265
| -0.3% | -$14.8K |
|
72
The Oncology Institute
TOI
$302M
| $3.83M | 0.08% |
3,360,052
| – | – |
|
73
HilleVax
HLVX
$105M
| $2.73M | 0.05% |
1,882,654
| – | – |
|
74
CalciMedica
CALC
$45M
| $2.48M | 0.05% |
1,300,000
| – | – |
|
75
BiomX
PHGE
$14.1M
| $1.39M | 0.03% |
2,494,108
+706,498
| +40% | +$393K |
|